Q2 2024 WAVE Life Sciences Ltd Earnings Call Transcript
Key Points
- WAVE Life Sciences Ltd (WVE) reported positive results from the SELECT-HD clinical trial for WVE-003, showing potent and durable mutant protein lowering in Huntington's disease.
- The company has initiated engagement with regulators on a clinical development path for WVE-003 that could support accelerated approval.
- WVE-N531, the exon-skipping candidate for Duchenne Muscular Dystrophy (DMD), demonstrated industry-leading exon skipping and unprecedented muscle concentrations in Part A of the clinical trial.
- WVE-006, the first-in-class GalNAc RNA editing candidate for AATD, has shown promising preclinical results, including increased wild-type protein levels and reduced liver aggregates.
- WVE-007, a novel siRNA approach for obesity, demonstrated highly potent and durable silencing in preclinical studies, with potential for infrequent dosing intervals of once or twice a year.
- WAVE Life Sciences Ltd (WVE) reported a net loss of $32.9 million for the second quarter of 2024, an increase from $21.1 million in the prior year quarter.
- Research and development expenses increased to $40.4 million, driven by spending on the INHBE program and other pipeline initiatives.
- The company faces significant scientific gaps in the functional benefits and durability of current DMD therapies, highlighting the need for better treatment options.
- There are uncertainties regarding the regulatory feedback and opt-in decision from Takeda, which could impact the future of the HD program.
- The competitive landscape for AATD treatments poses challenges, with questions about the translatability of preclinical dose-finding studies to humans.
Good morning, and welcome to the Wave Life Sciences second quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this call is being recorded and webcast. I'll now turn the call over to Kate Rausch, Vice President, Investor Relations and Corporate Affairs. Please go ahead.
Thank you, operator. Good morning, and thank you for joining us today to discuss our recent business progress and review Wave's second quarter 2024 financial results. Joining me today with prepared remarks are Dr. Paul Bolno, President and Chief Executive Officer; Anne-Marie Li-Kwai-Cheung, Chief Development Officer; and Kyle Moran, Chief Financial Officer. Erik Ingelsson, Chief Scientific Officer; Chandra Vargeese, Chief Technology Officer; and Ginnie Yang, SVP of Translational Medicine, will also be available for questions following the call.
The press release issued this morning is available on the Investors section of our website,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
